Skip to main content
. 2021 Jul 15;26(14):4301. doi: 10.3390/molecules26144301

Figure 8.

Figure 8

(A) Schematic of the structures of typical polyoxometalates: (a) Wells–Dawson structure, K8[P2CoW17O61]; (b) trivacant Keggin structure, α-Na9H-[SiW9O34]; (c) Anderson structure, Na5[IMo6O24]. Reprinted with permission from reference [117]. Copyright 2011 Wiley-VCH. (B) Schematic of the NIR-responsive rPOMDs@MSNs@copolymer acting as a multifunctional photothermal agent for the treatment of AD. Reprinted with permission from reference [125]. Copyright 2018 Wiley-VCH. (C) Schematic of the peptide–POM conjugates used for AD treatment. (a) The schematic illustration of self-assembly of Aβ15-20 and POM to hybrid spheres. (b) The assembled peptide and POM nanoparticles can effectively inhibit Aβ1-40 aggregation. Reprinted with permission from reference [126]. Copyright 2013 Wiley-VCH. (D) Schematic of the Aβ pathway influenced by AuNPs@POMD–peptide. Reprinted with permission from reference [127]. Copyright 2015 Wiley-VCH.